Thymosin Alpha-1

Mechanism

Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide naturally produced by the thymus gland and originally isolated from thymosin fraction 5 by Allan Goldstein. It modulates T-cell maturation and function — specifically promoting CD4+ and CD8+ T-cell development, enhancing Th1-type immune responses, and downregulating the chronic low-grade inflammatory signaling that characterizes immunosenescence and certain chronic disease states.

The evidence base is stronger and more clinical than most peptides in this catalog. Thymosin Alpha-1 is registered as Zadaxin in over 35 countries for treatment of hepatitis B and as an immune adjunct in cancer populations receiving chemotherapy. The mechanism is well-characterized: it acts as a thymic hormone signal, effectively telling the immune system to mature and organize its T-cell response, which is the opposite direction from immunosuppression. In older individuals or those post-illness, the thymic output decreases naturally, and Tα1 partially compensates.

Chronic inflammation is increasingly recognized as a driver of aging phenotypes across multiple organ systems. The argument for Tα1 in longevity stacks is that immunosenescence — the progressive dysregulation of immune function with age — is one of the most consistent features of biological aging, and addressing it through thymic signaling is more targeted than general anti-inflammatory approaches.

Typical protocol

• Starter: 1.6 mg SC twice weekly (e.g. Monday and Thursday) for 4 weeks during a high-stress period, post-illness recovery, or entry into immune support season.
• Advanced: 1.6 mg SC twice weekly for 6–8 weeks. Re-cycle seasonally — fall before exposure season, and again post-winter if needed. Some longevity users run one 4-week cycle quarterly.
• Cycle length: 4–8 weeks per run. Pause between cycles — not a continuous peptide. Seasonal cadence is the typical pattern.
• Reconstitution: 5 mg vial + 2 mL bacteriostatic water → 2.5 mg/mL. On a U-100 insulin syringe: 64 IU = 0.64 mL = 1.6 mg. Note that 1.6 mg is a relatively small volume — drawing precision matters. If you find the 0.64 mL draw difficult to hit consistently, reconstitute in 1 mL bacteriostatic water instead (→ 5 mg/mL, then 32 IU = 0.32 mL = 1.6 mg) for cleaner dose pulls.

Who it's for

Primary fit is immune wellness — seasonal immune support, post-illness (post-COVID, post-mono, post-infectious fatigue syndrome), and high-stress periods where immune suppression is a real risk. Secondary fit is longevity stacking for immunosenescence, particularly in users over 40 where thymic output has declined meaningfully. Complements epithalon in multi-axis longevity protocols covering thymus (Tα1) and pineal (epithalon) function simultaneously.

Stacks well with

• epithalon 10mg — complementary longevity pairing covering two distinct aging axes. Epithalon addresses the pineal/circadian/telomere axis; Tα1 addresses the thymic/immune axis. Both are pulsed, and cycles can be run concurrently or staggered — no mechanism conflict.

Watch-outs

• This is not an acute-infection treatment. Do not start a cycle when already febrile or actively infected — the window for preventive effect is before exposure season, not during active illness. Begin at least 2 weeks before your anticipated exposure window.
• Morning injection timing is preferred — natural immune signaling has circadian patterns and morning dosing aligns with the body's immune activation rhythm, though the difference is modest.
• Reconstitution precision matters at this dose size. Use the reconstitution note above to choose a bacteriostatic water volume that gives you a clean, unambiguous draw.